{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.204","value":"0.78"},{"groupId":"OG001","spread":"0.239","value":"0.78"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"238"},{"groupId":"OG001","value":"245"}],"units":"Participants"}],"title":"Baseline (BL)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.215","value":"0.00"},{"groupId":"OG001","spread":"0.222","value":"-0.03"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"205"},{"groupId":"OG001","value":"199"}],"units":"Participants"}],"title":"Change from BL at Cycle (C) 3 Day (D) 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.260","value":"-0.02"},{"groupId":"OG001","spread":"0.305","value":"-0.02"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"157"}],"units":"Participants"}],"title":"Change from BL at C6D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.232","value":"0.03"},{"groupId":"OG001","spread":"0.226","value":"-0.01"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"129"},{"groupId":"OG001","value":"117"}],"units":"Participants"}],"title":"Change from BL at C9D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.163","value":"0.02"},{"groupId":"OG001","spread":"0.261","value":"-0.05"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"88"}],"units":"Participants"}],"title":"Change from BL at C12D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.238","value":"-0.02"},{"groupId":"OG001","spread":"0.221","value":"0.01"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"61"}],"units":"Participants"}],"title":"Change from BL at C15D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.208","value":"-0.02"},{"groupId":"OG001","spread":"0.226","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"53"}],"units":"Participants"}],"title":"Change from BL at C18D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.208","value":"0.00"},{"groupId":"OG001","spread":"0.256","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"45"}],"units":"Participants"}],"title":"Change from BL at C21D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.157","value":"0.00"},{"groupId":"OG001","spread":"0.225","value":"0.02"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"41"}],"units":"Participants"}],"title":"Change from BL at C24D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.283","value":"-0.09"},{"groupId":"OG001","spread":"0.213","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"35"}],"units":"Participants"}],"title":"Change from BL at C27D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.315","value":"-0.03"},{"groupId":"OG001","spread":"0.256","value":"0.02"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"title":"Change from BL at C30D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.211","value":"-0.01"},{"groupId":"OG001","spread":"0.218","value":"-0.02"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"title":"Change from BL at C33D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.333","value":"-0.07"},{"groupId":"OG001","spread":"0.395","value":"-0.07"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"title":"Change from BL at C36D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.360","value":"-0.16"},{"groupId":"OG001","spread":"0.143","value":"0.02"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"title":"Change from BL at C39D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.262","value":"-0.09"},{"groupId":"OG001","spread":"0.309","value":"-0.13"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"title":"Change from BL at C42D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.262","value":"-0.12"},{"groupId":"OG001","spread":"0.069","value":"0.17"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"Change from BL at C45D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.000","value":"-0.07"},{"groupId":"OG001","spread":"0.087","value":"0.06"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"Change from BL at C48D1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"238"},{"groupId":"OG001","value":"245"}],"units":"Participants"}],"description":"The EQ-5D-5L comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. For each of the 5 dimensions, subject's responses are scored on a 5-point scale (1=no problem to 5=extreme problems). Change from baseline is being presented for EQ Index score. Index score is defined as a weighted combination of the levels of the 5-dimention scales, ranging from 0 to 1 (perfect health), with higher scores indicating better health-related quality of life. The United States value set from Pickard et al 2019 was used.","dispersionType":"Standard Deviation","groups":[{"description":"Participants were randomized to sabatolimab plus Azacitidine","id":"OG000","title":"Sabatolimab (MBG453) + Azacitidine"},{"description":"Participants were randomized to placebo plus Azacitidine","id":"OG001","title":"Placebo + Azacitidine"}],"paramType":"MEAN","populationDescription":"FAS population with non-missing baseline EQ-5D-5L assessments. For each post-baseline timepoint, FAS population with non-missing baseline and post-baseline EQ-5D-5L assessment. FAS comprised of all patients to whom study treatment had been assigned by randomization.","reportingStatus":"POSTED","timeFrame":"Baseline, every 3 cycles up to C48D1 (1 cycle = 28 days)","title":"Change From Baseline in the European Quality of Life (EuroQol) - 5 Dimensions, 5 Level Questionnaire (EQ-5D-5L) Score Over Time","type":"SECONDARY","unitOfMeasure":"Scores on a scale"}